Structurally distinct cyclosporin and sanglifehrin analogs CRV431 and NV556 suppress established HCV infection in humanized-liver mice

• Michael Bobardt,

  Roles Methodology

  Affiliation Department of Immunology & Microbiology, The Scripps Research Institute, La Jolla, California, United States of America

  ⨯
• Magnus Joakim Hansson,

  Roles Writing – review & editing

  Affiliation NeuroVive Pharmaceutical AB, Lund, Sweden

  ⨯
• Patrick Mayo,

  Roles Formal analysis

  Affiliation Hepion Pharmaceuticals, Edison, New Jersey, United States of America

  ⨯
• Daren Ure,

  Roles Writing – review & editing

  Affiliation Hepion Pharmaceuticals, Edison, New Jersey, United States of America

  ⨯
• Robert Foster,

  Roles Writing – review & editing

  Affiliation Hepion Pharmaceuticals, Edison, New Jersey, United States of America

  ⨯
• Philippe Gallay

  Roles Conceptualization, Formal analysis, Investigation, Supervision, Validation, Visualization, Writing – original draft

  * E-mail: gallay@scripps.edu

  Affiliation Department of Immunology & Microbiology, The Scripps Research Institute, La Jolla, California, United States of America

  http://orcid.org/0000-0002-6151-4764

  ⨯